Cafepharma Today

May 16 2025 - Novo CEO to depart as obesity drugmaker’s challenges rise
Novo CEO to depart as obesity drugmaker’s challenges rise
BioMarin expands enzyme expertise with $270M Inozyme buy
Amgen could owe Regeneron more than $400M after defeat in cholesterol drug antitrust suit
Eli Lilly collaborates with Rznomics on hearing loss treatment in $1.3 billion pact
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Rigel Pharma prices public offering of stock at $9.50 per share, shares tumble on news
Yahoo/AP
Wednesday, October 3, 2012 - 12:35pm
tags:
Rigel Pharmaceuticals, stock offering
Opko's 4KScore Could Generate Over $1.8 Billion Annually
Seeking Alpha
Wednesday, October 3, 2012 - 12:34pm
tags:
GSK, JNJ, OPKO Health, Merck, Novartis, Pfizer, Sanofi, prostate cancer, 4Kscore
Sarepta's Next Step: Early FDA Approval
TheStreet.com
Wednesday, October 3, 2012 - 12:18pm
tags:
FDA, Sarepta, Duchenne Muscular Dystrophy, eteplirsen
Merck's once-a-week diabetes drug effective in clinical study
Reuters
Wednesday, October 3, 2012 - 11:21am
tags:
Merck, diabetes, MK-3102
Lpath Begins iSONEP Dosing in Nexus Phase 2 Study
Yahoo
Wednesday, October 3, 2012 - 11:21am
tags:
Lpath, iSONEP, wet-AMD, monoclonal antibodies
Exelixis: First Partnered Program Enters Phase III
Seeking Alpha
Wednesday, October 3, 2012 - 11:20am
tags:
Exelixis, Roche, GSK, GDC-0973, MEK inhibitor, melanoma
Reconsidering Zalicus And Antares In Light Of Shakeups
Seeking Alpha
Wednesday, October 3, 2012 - 10:56am
tags:
Zalicus, Antares Pharma, Acadia, Novartis, Pfizer, Sanofi
Neurocrine's VMAT-2 Enters Phase IIb
Seeking Alpha
Wednesday, October 3, 2012 - 10:52am
tags:
Neurocrine, Abbott Labs, tardive dyskinesia, NBI-98854, VMAT-2 inhibitor
U.S. judge accepts Abbott misbranding settlement
Reuters
Wednesday, October 3, 2012 - 10:51am
tags:
Abbott Labs, settlements, misbranding, Depakote
Bristol-Myers Squibb - Between Patent Deadlines And Revenue Shifts
Seeking Alpha
Wednesday, October 3, 2012 - 10:50am
tags:
patents, Bristol-Myers Squibb, Amylin, AstraZeneca, Novo Nordisk, Eli Lilly, Merck
Mylan Sues FDA for Approval of Generic Version of Diovan
Bloomberg
Wednesday, October 3, 2012 - 10:48am
tags:
FDA, Mylan, Diovan, generics, Ranbaxy, Novartis
Antares Pharma says it will sell stock to raise research funds; gets $750K payment from Pfizer
Yahoo/AP
Wednesday, October 3, 2012 - 10:47am
tags:
Pfizer, Antares Pharma, stock offering, Vibex QST gel
IPO Preview: Regulus Therapeutics
Seeking Alpha
Wednesday, October 3, 2012 - 10:45am
tags:
IPOs, Regulus, AstraZeneca
AstraZeneca Will Rise Again
Seeking Alpha
Wednesday, October 3, 2012 - 10:44am
tags:
AstraZeneca
Lundbeck, Takeda seek U.S. approval for antidepressant
Chicago Tribune, IL
Tuesday, October 2, 2012 - 12:17pm
tags:
Takeda, Lundbeck, antidepressants, vortioxetine
Abbott CEO: Gonzalez Resume Was An Error
Pharmalot
Tuesday, October 2, 2012 - 12:16pm
tags:
Richard Gonzalez, Abbott Labs, AbbVie
POZEN patents upheld in Treximet patent litigation appeal
The Fly on the Wall
Tuesday, October 2, 2012 - 12:13pm
tags:
Pozen, patents, Treximet, generics
Lessons From Biotech's Best Third Quarter Stocks
TheStreet.com
Tuesday, October 2, 2012 - 11:59am
tags:
Celsion, XenoPort, Peregrine Pharmaceuticals, Sunesis, Opexa, StemCells, Catalyst Pharmaceutical Partners, Hemispherx, Sarepta, Savient
Roche declines comment on report of Illumina bid, Bloomberg reports
Yahoo/Fly on the Wall
Tuesday, October 2, 2012 - 11:57am
tags:
Roche, Illumina, M&A
Illumina Rises On Unusually High Volume
TheStreet.com
Tuesday, October 2, 2012 - 11:56am
tags:
Illumina

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.